Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx’s existing investors, will maintain its investment in ImpactRx.
Under the terms of the acquisition ImpactRx will operate as an independent STG portfolio company.
STG MD JT Treadwell said the company’s mission is to invest in companies with a compelling set of assets and capabilities, and solid client relationships, and work closely with management to deliver solutions to customers and increase company growth.
ImpactRx president and CEO Richard Altus said STG will help ImpactRx to improve in evaluating and interpreting the drivers of physician behavior, as well as help us expand their reach and scope as a partner to customers.
"In addition, integrating our proprietary syndicated data set with external secondary and custom data resources, leveraging STG’s vast data modeling and analytics expertise, will enable us to deliver the comprehensive, multi-channel solutions our clients need to grow their businesses in today’s complicated and competitive biopharmaceutical marketplace," Altus said.